Literature DB >> 3131471

Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

S J Cryz1, J C Sadoff, D Ohman, E Fürer.   

Abstract

We characterized the immune response in humans after vaccination with a Pseudomonas aeruginosa immunotype 5 O-polysaccharide (O-PS)-toxin A conjugate vaccine. The majority of volunteers responded with an immunoglobulin G (IgG) antibody response on enzyme-linked immunosorbent assay (ELISA) to both the toxin A and the lipopolysaccharide (LPS) components of the vaccine. Maximal titers to both vaccine components were seen 42 days after immunization. Antibody levels remained elevated for at least 14 months after vaccination. The anti-LPS IgG response was predominantly within the IgG1 and IgG2 subclasses, whereas the antitoxin A response was within the IgG1 subclass. There was a gradual elevation of IgG4 antitoxin antibody, with maximal levels seen at 14 months after immunization. No concomitant IgG4 antibody rise to LPS was observed. Immunization evoked a vigorous IgA1 and IgA2 antibody response to LPS, which was long-lived. Only a modest, transient IgA antitoxin A response was noted. Both antitoxin A--neutralizing and opsonic antibodies were elicited by immunization and remained elevated over the 14-month postimmunization period studied.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3131471

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Authors:  A W Zuercher; M A Imboden; S Jampen; D Bosse; M Ulrich; H Chtioui; B H Lauterburg; A B Lang
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 2.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

3.  Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Authors:  E Mansouri; J Gabelsberger; B Knapp; E Hundt; U Lenz; K D Hungerer; H E Gilleland; J Staczek; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

4.  Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Authors:  A W Zuercher; M A Imboden; S Jampen; D Bosse; M Ulrich; H Chtioui; B H Lauterburg; A B Lang
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

5.  Purification and characterization of phosphomannomutase/phosphoglucomutase from Pseudomonas aeruginosa involved in biosynthesis of both alginate and lipopolysaccharide.

Authors:  R W Ye; N A Zielinski; A M Chakrabarty
Journal:  J Bacteriol       Date:  1994-08       Impact factor: 3.490

Review 6.  Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.

Authors:  Gerald B Pier
Journal:  Int J Med Microbiol       Date:  2007-04-27       Impact factor: 3.473

7.  Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.

Authors:  B U von Specht; B Knapp; G Muth; M Bröker; K D Hungerer; K D Diehl; K Massarrat; A Seemann; H Domdey
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

8.  Synthesis of lipopolysaccharide O side chains by Pseudomonas aeruginosa PAO1 requires the enzyme phosphomannomutase.

Authors:  J B Goldberg; K Hatano; G B Pier
Journal:  J Bacteriol       Date:  1993-03       Impact factor: 3.490

9.  Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.

Authors:  A W Cripps; M L Dunkley; R L Clancy
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.